These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 8651045)

  • 21. Long-term treatment with fenfluramine in obese subjects.
    Sensi S; Della Loggia F; Del Ponte A; Guagnano MT
    Int J Clin Pharmacol Res; 1985; 5(4):247-53. PubMed ID: 4055167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of drugs used to treat obesity on the autonomic nervous system.
    Hirsch J; Mackintosh RM; Aronne LJ
    Obes Res; 2000 May; 8(3):227-33. PubMed ID: 10832765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine and metabolic effects of dexfenfluramine in patients with android obesity.
    Ditschuneit HH; Flechtner-Mors M; Dolderer M; Fulda U; Ditschuneit H
    Horm Metab Res; 1993 Nov; 25(11):573-8. PubMed ID: 8288160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the mechanism of action of dexfenfluramine: effect on alliesthesia and appetite motivation in lean and obese subjects.
    Blundell JE; Hill AJ
    Clin Neuropharmacol; 1988; 11 Suppl 1():S121-34. PubMed ID: 3180107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of dexfenfluramine in obese patients: a multicenter study.
    Enzi G; Crepaldi G; Inelmen EM; Bruni R; Baggio B
    Clin Neuropharmacol; 1988; 11 Suppl 1():S173-8. PubMed ID: 3052815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of conjugated linoleic acid supplementation after weight loss on appetite and food intake in overweight subjects.
    Kamphuis MM; Lejeune MP; Saris WH; Westerterp-Plantenga MS
    Eur J Clin Nutr; 2003 Oct; 57(10):1268-74. PubMed ID: 14506488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
    Davis R; Faulds D
    Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dexfenfluramine hydrochloride: an anorexigenic agent.
    Bever KA; Perry PJ
    Am J Health Syst Pharm; 1997 Sep; 54(18):2059-72. PubMed ID: 9377205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K; Finer N; Rössner S
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation and treatment of obesity in clinical practice].
    Keller U; van der Werf H; Stohler R
    Ther Umsch; 1989 May; 46(5):297-308. PubMed ID: 2741131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexfenfluramine reduces cardiovascular risk factors.
    Bremer JM; Scott RS; Lintott CJ
    Int J Obes Relat Metab Disord; 1994 Apr; 18(4):199-205. PubMed ID: 8044193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study)].
    Payer J; Hainer V; Ondrejka P; Kajtor Z
    Vnitr Lek; 2004 Nov; 50(11):825-9. PubMed ID: 15648961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women.
    McLaughlin T; Abbasi F; Kim HS; Lamendola C; Schaaf P; Reaven G
    Metabolism; 2001 Jul; 50(7):795-800. PubMed ID: 11436184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
    Lafreniere F; Lambert J; Rasio E; Serri O
    Int J Obes Relat Metab Disord; 1993 Jan; 17(1):25-30. PubMed ID: 8383638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Judicious use of anorectics].
    Laurent-Jaccard A
    Schweiz Rundsch Med Prax; 1991 Feb; 80(6):116-7. PubMed ID: 2003174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans.
    Fogteloo AJ; Pijl H; Frölich M; McCamish M; Meinders AE
    Diabetes Nutr Metab; 2003 Apr; 16(2):109-14. PubMed ID: 12846450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.